InMed Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 17, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Capitalization	3	4	2	3	10	26
Market Cap Growth	50.40%	65.68%	-23.21%	-68.01%	-62.35%	-20.62%
Enterprise Value	-3	0	-4	-6	5	16
Last Close Price	0.88	3.25	5.31	18.53	235.20	1590.00
PS Ratio	0.55	0.79	0.52	0.75	8.85	-
PB Ratio	0.26	0.29	0.26	0.26	1.06	3.47
P/TBV Ratio	0.43	0.33	0.32	0.30	1.38	4.05
EV/Sales Ratio	-	0.01	-	-	4.24	-
Debt / Equity Ratio	0.06	0.06	0.11	0.03	0.09	0.04
Net Debt / Equity Ratio	-0.67	-0.77	-0.61	-0.71	-0.60	-0.97
Net Debt / EBITDA Ratio	0.85	1.35	0.71	1.05	0.41	0.73
Net Debt / FCF Ratio	0.87	1.34	0.81	1.15	0.35	0.73
Asset Turnover	0.46	0.36	0.36	0.31	0.10	-
Inventory Turnover	3.09	2.94	2.44	1.33	-	-
Quick Ratio	4.85	6.30	3.53	4.61	1.90	3.35
Current Ratio	5.94	6.99	4.41	5.66	2.89	3.78
Return on Equity (ROE)	-97.20%	-72.10%	-72.08%	-75.09%	-226.07%	-153.95%
Return on Assets (ROA)	-49.77%	-36.12%	-39.22%	-38.94%	-75.28%	-70.65%
Return on Capital Employed (ROCE)	-80.70%	-57.60%	-82.60%	-69.20%	-143.60%	-131.40%
Earnings Yield	-221.57%	-208.04%	-324.14%	-257.74%	-192.96%	-39.86%
FCF Yield	-214.56%	-197.97%	-295.41%	-241.44%	-162.08%	-38.25%
Buyback Yield / Dilution	-391.70%	-156.13%	-211.26%	-336.59%	-108.64%	-28.72%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q